EFFECTS OF SEMAGLUTIDE ON FAT AND MUSCLE MASS LOSS

Authors

  • Ana Carolina Cerqueira Costa
  • Elaine Souza dos Santos Universidade UniRedentor AFYA
  • David Capachi Alvim Faculdade Afya Ciências Médicas da Paraíba
  • Priscila Leite Loiola Ribeiro FMC
  • Yean Henrique Manhães Neves Unig
  • Ana Cristina Guedes de Freitas Unigranrio Afya Duque de Caxias https://orcid.org/0000-0001-5659-3560
  • Fernanda Bortoli Arlota Unigranrio Afya Duque de Caxias https://orcid.org/0009-0001-2237-7736
  • Marina Rodrigues Farage Unigranrio Afya Duque de Caxias
  • Layla de Oliveira Rangel
  • Lídia Benevides Lima Garcia Redentor Afya
  • Julyana Krüger Pilon Acadêmica de Medicina - Faculdade Santo Agostinho Vitória da Conquista - AFYA
  • Theo Rezende Camargo Acadêmico de medicina - Universidade UniCEUB

DOI:

https://doi.org/10.36557/2674-8169.2024v6n2p2018-2035

Keywords:

obesity; semaglutide; GLP-1 receptor agonists.

Abstract

Obesity is a highly complex multifactorial condition, related to genetic factors, improper diet, and excessive consumption of processed foods in association with a sedentary lifestyle. This condition can be managed through diet, physical exercise, bariatric surgery, and medication, always under the supervision of a qualified professional and ideally, a multidisciplinary team. The use of non-drug interventions alone is not always sufficient in the long term. In this context, GLP-1 receptor antagonists (GLP-1 RAs), especially semaglutide, emerge as a potential ally in enhancing weight loss. The medication works by activating anorexigenic neurotransmitters, resulting in reduced appetite and caloric intake, demonstrating greater efficacy compared to other antidiabetic agents in reducing glucose levels and promoting weight loss. The choice of this topic is justified by the need to elucidate the potential effects of this medication on fat and muscle loss and to enhance knowledge as a basis for conscious prescription, appropriate use, and monitoring of possible adverse effects. This study was developed based on a descriptive narrative review and qualitative approach, allowing the compilation of all knowledge produced on the subject and addressing the study's objectives. It can be observed that semaglutide appears to be a promising ally in the process of weight and body fat loss. However, many patients have experienced significant loss of muscle mass, skin flaccidity, and aesthetic impairments when using this medication. Regarding weight loss and glycemic control, studies consistently show that semaglutide use is highly effective and safe. As for side effects, the most documented ones in the literature are gastrointestinal, especially nausea and vomiting. Further research is needed to confirm whether HMB supplementation would result in a reduction of sarcopenia in patients with significant weight loss caused by semaglutide use. On the other hand, collagen bio-stimulators seem to be a valuable resource in clinical practice, offering a minimally invasive and safe alternative to aesthetic surgery. Lifestyle changes, including improved dietary quality and regular physical exercise, are essential allies to drug therapy to ensure the long-term success of the treatment.

Downloads

Download data is not yet available.

References

- DE OLIVEIRA, C. B. C. et al. Obesidade: inflamação e compostos bioativos. Journal of Health & Biological Sciences, v. 8, n. 1, p. 1-5, 2020. Disponível em: https://periodicos.unichristus.edu.br/jhbs/article/view/2785. Acesso em: 29 abr. 2023.

- MINISTÉRIO DA SAÚDE. Você sabe a diferença entre sobrepeso e obesidade? 2021. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-brasil/eu-quero-ter-peso-saudavel/noticias/2021/voce-sabe-a-diferenca-entre-sobrepeso-e-obesidade. Acesso em: 29 abr. 2023.

- ABESO. Mapa da Obesidade. São Paulo, 2019. Disponível em: Mapa da Obesidade - Abeso . Acesso em: 12 mai. 2023.

- Sistema de Vigilância Alimentar e Nutricional -SISVAN/ MINISTÉRIO DA SAÚDE. ÍNDICE DE MASSA CORPORAL BRASIL 2022. Disponível em: https://www.sbcbm.org.br/obesidade-atinge-mais-de-67-milhoes-de-pessoas-no-brasil-em-2022/#:~:text=Dados%20do%20Minist%C3%A9rio%20da%20Sa%C3%BAde,863.086%20pessoas%20no%20ano%20passado. Acesso em: 06 maio 2023.

- WELLS, J. C. The diabesity epidemic in the light of evolution: insights from the capacity–load model. Diabetologia, v. 62, n. 10, p. 1740-1750, 2019. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731192/. Acesso em: 07 jun 2023.

- KANE, M. P.; TRIPLITT, C. L.; SOLIS, H. C. D. Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. American Journal of HealthSystem Pharmacy, 78(7), 556-567, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33354706/. Acesso em: 07 jun 2023.

- KNUDSEN, Lotte Bjerre. Lau, Jesper. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 2019. Vol.10. Article 155. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474072/pdf/fendo-10-00155.pdf Acesso em: 07 jun 2023.

- PAIM, MARINA BASTOS; KOVALESKI, DOUGLAS FRANCISCO. Análise das diretrizes brasileiras de obesidade: patologização do corpo gordo, abordagem focada na perda de peso e gordofobia. Saúde e Sociedade, v. 29, p. e190227, 2020. Disponível em: https://www.scielo.br/j/sausoc/a/pBvf5Zc6vtkMSHytzLKxYJH/?format=pdf&lang=pt. Acesso em: 02 jun 2023.

- GUIMARÃES, P. S.; SILVA, R. S. O preço da perfeição. Revista Pet Economia UFES, v. 2, n. 1, p. 14-17, 2021. Disponível em: https://periodicos.ufes.br/peteconomia/article/view/36427. Acesso em: 05 maio 2023.

- JORNAL O SUL. Face de Ozempic: novas drogas contra obesidade fazem o rosto “despencar”. 11 de março de 2023. Disponível em: https://www.osul.com.br/face-de-ozempic-novas-drogas-contra-obesidade-fazem-o-rosto-despencar/. Acesso em: 06 maio 2023.

- ZHANG, Xueli; Zhao, Yi; Chen, Shuobing; Shao, Hua. Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. Journal of Cachexia, Sarcopenia and Muscle 2021; 12: 1368–1379. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718027/pdf/JCSM-12-1368.pdf Acesso em: 06 maio 2023.

- SOEIRO, R. L. Educação em Saúde em Grupo no Tratamento de Obesos Grau III: um Desafio para os Profissionais de Saúde. Revista bras. educ. med. 2019. Disponível em: https://www.scielo.br/j/rbem/a/g8BsTSptPz6NvsB63phJXms/?lang=pt Acesso em: 07 jun. 2023.

Published

2024-02-23

How to Cite

Costa, A. C. C., Santos, E. S. dos, Alvim, D. C., Ribeiro, P. L. L., Neves, Y. H. M., Freitas, A. C. G. de, Arlota, F. B., Farage, M. R., Rangel, L. de O., Garcia, L. B. L., Pilon, J. K., & Camargo, T. R. (2024). EFFECTS OF SEMAGLUTIDE ON FAT AND MUSCLE MASS LOSS. Brazilian Journal of Implantology and Health Sciences, 6(2), 2018–2035. https://doi.org/10.36557/2674-8169.2024v6n2p2018-2035

Issue

Section

Original article